drugset / Trial / NCT04433585

A Study of LY3471851 in Adults With Systemic Lupus Erythematosus (SLE)

NCT04433585

Phase 2 Completed 291 enrolled Nektar Therapeutics Eli Lilly and Company · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

The reason for this study is to see if the study drug LY3471851 (NKTR-358) is safe and effective in adults with systemic lupus erythematosus (SLE).

Timeline

Start
2020-08-19
Primary completion
2023-01-10
Completion
2023-02-16

Drugs

EvaluationDrugModalityDoseRoute
Subject Rezpegaldesleukin Protein / enzyme biologic Subcutaneous